Sirius Genomics Announces Issuance of U.S. Patent
Sirius Genomics announced that U.S. Patent No. 7,820,376 entitled "Protein C Polymorphisms" has been issued by the United States Patent and Trademark Office. The patent relates to a novel use of a Single Nucleotide Polymorphism (SNP) located in the Protein C gene.
"The patent covers methods of predicting outcome or prognosis in sepsis, and other related conditions, by determining a subject's genotype at the SNP. This patent issuance further strengthens Sirius' patent portfolio and position as a developer of companion diagnostics," stated Dr. Jennifer Kaufman-Shaw, Vice President, Intellectual Property at Sirius Genomics.
"Sirius Genomics' steadily expanding patent estate stems from discoveries made from the Company's focused approach in the identification and validation of genetic markers linked to drug response. Our focus is on improving outcomes for patients treated with various classes of drugs used in the acute care setting," stated Chris Wagner, President and CEO of Sirius Genomics.
Sirius' intellectual property portfolio includes patent families related to several therapies available and under development for sepsis and other acute conditions.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Last viewed contents

Verder Group acquires ERWEKA - With this acquisition, Verder Scientific expands its portfolio to include dissolution and tablet testing equipment for the pharmaceutical and life science sectors
Primary_ciliary_dyskinesia
Evotec and CHDI Foundation, Inc. Extend Collaboration to Fight Huntington’s Disease
Leukocare appoints VP Business Development - Expands team and relocates operations to the IZB in Martinsried/Munich
Researchers trace HIV mutations that lead to drug resistance
Non-alcoholic_fatty_liver_disease
High-Tech Gruenderfonds invests in agricultural biotechnology startup
Anti-glycoprotein-210_antibodies
